Smoking-induced change in intrasynaptic dopamine concentration: Effect of treatment for Tobacco Dependence

[1]  S. Shiffman,et al.  Psychological mediators of bupropion sustained-release treatment for smoking cessation. , 2008, Addiction.

[2]  M. Goolsby,et al.  Treating Tobacco Use and Dependence , 2008, Pediatrics.

[3]  Iwao Kanno,et al.  Enhanced dopamine release by nicotine in cigarette smokers: a double-blind, randomized, placebo-controlled pilot study. , 2008, The international journal of neuropsychopharmacology.

[4]  C. Cepeda,et al.  Repeated Exposure to Methamphetamine Causes Long-Lasting Presynaptic Corticostriatal Depression that Is Renormalized with Drug Readministration , 2008, Neuron.

[5]  H. Fukuyama,et al.  Temporal Change in Human Nicotinic Acetylcholine Receptor After Smoking Cessation: 5IA SPECT Study , 2007, Journal of Nuclear Medicine.

[6]  Alice Egerton,et al.  The effect of nicotine on striatal dopamine release in man: A [11C]raclopride PET study , 2007, Synapse.

[7]  R. P. Maguire,et al.  Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[8]  D. Balfour,et al.  Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell , 2007, The European journal of neuroscience.

[9]  Robert A Koeppe,et al.  Smoking Modulation of μ-Opioid and Dopamine D2 Receptor-Mediated Neurotransmission in Humans , 2007, Neuropsychopharmacology.

[10]  R. Kast,et al.  Bupropion: pharmacology and therapeutic applications , 2006, Expert review of neurotherapeutics.

[11]  Edythe D London,et al.  Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens. , 2006, Archives of general psychiatry.

[12]  J. McCormack,et al.  Outcomes of Bupropion Therapy for Smoking Cessation During Routine Clinical Use , 2006, The Annals of pharmacotherapy.

[13]  A. Tanács,et al.  Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study. , 2005, Journal of affective disorders.

[14]  Darin D Dougherty,et al.  Neuroimaging and the functional neuroanatomy of psychotherapy , 2005, Psychological Medicine.

[15]  Alain Dagher,et al.  The hedonic response to cigarette smoking is proportional to dopamine release in the human striatum as measured by positron emission tomography and [11C]raclopride , 2004, Synapse.

[16]  A. Grace,et al.  The Catechol-O-Methyltransferase Polymorphism: Relations to the Tonic–Phasic Dopamine Hypothesis and Neuropsychiatric Phenotypes , 2004, Neuropsychopharmacology.

[17]  E. Hudes,et al.  Bupropion for smoking cessation: a randomized trial. , 2004, Archives of internal medicine.

[18]  Jeffrey H. Meyer,et al.  Smoking-induced ventral striatum dopamine release. , 2004, The American journal of psychiatry.

[19]  S. Janhunen,et al.  Comparison of the effects of nicotine and epibatidine on the striatal extracellular dopamine. , 2004, European journal of pharmacology.

[20]  S. Holmes,et al.  Bupropion as an aid to smoking cessation: a review of real‐life effectiveness , 2004, International journal of clinical practice.

[21]  Richard E Carson,et al.  Nicotine-Induced Dopamine Release in Primates Measured with [11C]Raclopride PET , 2004, Neuropsychopharmacology.

[22]  S. Haber,et al.  Imaging Human Mesolimbic Dopamine Transmission with Positron Emission Tomography. Part II: Amphetamine-Induced Dopamine Release in the Functional Subdivisions of the Striatum , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[23]  S. Hall,et al.  Psychological intervention and antidepressant treatment in smoking cessation. , 2002, Archives of general psychiatry.

[24]  P. B. Gold,et al.  Naturalistic, self-assignment comparative trial of bupropion SR, a nicotine patch, or both for smoking cessation treatment in primary care. , 2002, The American journal on addictions.

[25]  Hideo Tsukada,et al.  Comparative effects of methamphetamine and nicotine on the striatal [11C]raclopride binding in unanesthetized monkeys , 2002, Synapse.

[26]  Nathalie Ginovart,et al.  Effects of Amphetamine and Evoked Dopamine Release on [11C]raclopride Binding in Anesthetized Cats , 2002, Neuropsychopharmacology.

[27]  Osama Mawlawi,et al.  Imaging Human Mesolimbic Dopamine Transmission with Positron Emission Tomography: I. Accuracy and Precision of D2 Receptor Parameter Measurements in Ventral Striatum , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[28]  A. Lajtha,et al.  Differences in Nicotine-Induced Dopamine Release and Nicotine Pharmacokinetics Between Lewis and Fischer 344 Rats , 2001, Neurochemical Research.

[29]  D. Balfour,et al.  THE PHARMACOLOGY UNDERLYING PHARMACOTHERAPY FOR TOBACCO DEPENDENCE: A FOCUS ON BUPROPION , 2001, International journal of clinical practice.

[30]  M. Jarvik,et al.  Nicotine Blood Levels and Subjective Craving for Cigarettes , 2000, Pharmacology Biochemistry and Behavior.

[31]  C. Spencer,et al.  Bupropion , 2000, Drugs.

[32]  W C Eckelman,et al.  Measurement of dopamine release with continuous infusion of [11C]raclopride: optimization and signal-to-noise considerations. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  Aker,et al.  A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. , 1999, The New England journal of medicine.

[34]  J D Brodie,et al.  A pharmacologic strategy for the treatment of nicotine addiction , 1999, Synapse.

[35]  S. Preskorn,et al.  Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. , 1998, Journal of Affective Disorders.

[36]  G Blomqvist,et al.  Comparison of the Transient Equilibrium and Continuous Infusion Method for Quantitative PET Analysis of [11C]Raclopride Binding , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[37]  M. Palkovits,et al.  Localization and Dynamic Regulation of Biogenic Amine Transporters in the Mammalian Central Nervous System , 1998, Frontiers in Neuroendocrinology.

[38]  G D Pearlson,et al.  PET study of competition between intravenous cocaine and [11C]raclopride at dopamine receptors in human subjects. , 1997, The American journal of psychiatry.

[39]  M. Benwell,et al.  Regional variation in the effects of nicotine on catecholamine overflow in rat brain. , 1997, European journal of pharmacology.

[40]  W C Eckelman,et al.  Quantification of Amphetamine-Induced Changes in [11C]Raclopride Binding with Continuous Infusion , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[41]  A. Lammertsma,et al.  Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.

[42]  G. Chiara,et al.  Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs , 1996, Nature.

[43]  J. Feighner,et al.  Bupropion: a review of its mechanism of antidepressant activity. , 1995, The Journal of clinical psychiatry.

[44]  K. Schuh,et al.  Desire to smoke during spaced smoking intervals , 1995, Psychopharmacology.

[45]  R L Stout,et al.  Ensuring balanced distribution of prognostic factors in treatment outcome research. , 1994, Journal of studies on alcohol. Supplement.

[46]  Jean Logan,et al.  Imaging endogenous dopamine competition with [11C]raclopride in the human brain , 1994, Synapse.

[47]  D. Wetter,et al.  Two studies of the clinical effectiveness of the nicotine patch with different counseling treatments. , 1994, Chest.

[48]  T. Svensson,et al.  Systemic nicotine‐induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area , 1994, Synapse.

[49]  J. Mazziotta,et al.  MRI‐PET Registration with Automated Algorithm , 1993, Journal of computer assisted tomography.

[50]  L. Kozlowski,et al.  The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. , 1991, British journal of addiction.

[51]  T. Carmody.  Preventing relapse in the treatment of nicotine addiction: current issues and future directions. , 1990, Journal of psychoactive drugs.

[52]  H. Fibiger,et al.  Acute effects of bupropion on extracellular dopamine concentrations in rat striatum and nucleus accumbens studied by in vivo microdialysis. , 1989, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[53]  H. Fibiger,et al.  Lack of tolerance to nicotine-induced dopamine release in the nucleus accumbens. , 1989, European journal of pharmacology.

[54]  G. Di Chiara,et al.  Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[55]  M. Benwell,et al.  Evidence that Tobacco Smoking Increases the Density of (−)‐[3H]Nicotine Binding Sites in Human Brain , 1988, Journal of neurochemistry.

[56]  T. Högberg,et al.  Synthesis of [methoxy-3H]- and [methoxy-11C]- labelled raclopride. Specific dopamine-D2 receptor ligands , 1987 .

[57]  G. Di Chiara,et al.  Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. , 1986, European journal of pharmacology.

[58]  A. Washton.  Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviors , 1986 .

[59]  G. Sedvall,et al.  Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. , 1986, Science.

[60]  M. Hamilton,et al.  Development of a rating scale for primary depressive illness. , 1967, The British journal of social and clinical psychology.

[61]  J. Monterosso,et al.  Ventral Striatal Dopamine Release in Response to Smoking a Regular vs a Denicotinized Cigarette , 2009, Neuropsychopharmacology.

[62]  T. Poeppel,et al.  Investigating the Dopaminergic Synapse In Vivo. I. Molecular Imaging Studies in Humans , 2007, Reviews in the neurosciences.

[63]  C. Antke,et al.  Investigating the Dopaminergic Synapse In Vivo. II. Molecular Imaging Studies in Small Laboratory Animals , 2007, Reviews in the neurosciences.

[64]  Dennis M. Donovan,et al.  Relapse prevention: Maintenance strategies in the treatment of addictive behaviors, 2nd ed. , 2005 .

[65]  Richard A. Brown,et al.  The Tobacco Dependence Treatment Handbook: A Guide to Best Practices. By D. B. Abrams, R. , 2004 .

[66]  Stephen M. Stahl,et al.  A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. , 2004, Primary care companion to the Journal of clinical psychiatry.

[67]  L. Stead,et al.  Group behaviour therapy programmes for smoking cessation. , 2000, The Cochrane database of systematic reviews.

[68]  J. Kay,et al.  Some neurobiological aspects of psychotherapy. A review. , 1999, The Journal of psychotherapy practice and research.

[69]  D. Schroeder,et al.  A comparison of sustained-release bupropion and placebo for smoking cessation. , 1997, The New England journal of medicine.

[70]  M. First,et al.  Structured clinical interview for DSM-IV axis I disorders : SCID-I : clinical version : scoresheet , 1997 .

[71]  M. First,et al.  Structured Clinical Interview for DSM-IV Axis I Disorders , 1997 .

[72]  F. Amini,et al.  Affect, attachment, memory: contributions toward psychobiologic integration. , 1996, Psychiatry.

[73]  K. Fagerström,et al.  Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. , 1978, Addictive behaviors.

[74]  A. C. Collins,et al.  Effect of Smoking History on [ 3 H]nicotine Binding in Human Postmortem Brain 1 , 2022 .